Trulieve Cannabis (TRLV) EBITDA Margin (2020 - 2026)

Trulieve Cannabis has reported EBITDA Margin for 7 years, with the latest figure at 136.75% in Q2 2026.

• On a quarterly basis, EBITDA Margin fell 15417.0% year-over-year to 136.75% in Q2 2026; TTM through Jun 2026 was 24.34%, a 3176.0% decrease from a year earlier, with the FY2025 full-year figure at 16.64%, up 407.0% from the prior year.
• EBITDA Margin was 136.75% for Q2 2026 at Trulieve Cannabis, down from 12.46% in the prior quarter.
• The five-year high for EBITDA Margin was 19.62% in Q2 2022, with the low at 136.75% in Q2 2026.
• Average EBITDA Margin over 5 years is 3.38%, with a median of 12.83% recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: EBITDA Margin surged 11977 bps in 2024, then plunged 15417 bps in 2026.
• Over 5 years, EBITDA Margin stood at 10.05% in 2022, then jumped by 63 bps to 16.38% in 2023, then slumped by 97 bps to 0.43% in 2024, then soared by 1101 bps to 5.22% in 2025, then slumped by 2721 bps to 136.75% in 2026.
• The last three EBITDA Margin figures came in at 136.75% (Q2 2026), 12.46% (Q1 2026), and 5.22% (Q4 2025), per Business Quant data.